{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:52:50Z","timestamp":1791219170493,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00262-019-02307-x","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T07:15:11Z","timestamp":1549869311000},"page":"773-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3470-1318","authenticated-orcid":false,"given":"Linh T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Saibil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Sotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael X.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Ghazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habeeb","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Habeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wey","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Easson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yasufuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Cypel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianzheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Boross-Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Nelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fyrsta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Hua","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha R.","family":"Elford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Effendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragitha","family":"Ellenchery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-7057","authenticated-orcid":false,"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"issue":"6230","key":"2307_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62\u201368. \n                    https:\/\/doi.org\/10.1126\/science.aaa4967","journal-title":"Science"},{"issue":"13","key":"2307_CR2","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2307_CR3","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","volume":"18","author":"LG Radvanyi","year":"2012","unstructured":"Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758\u20136770. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1177","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2307_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","volume":"35","author":"S Pilon-Thomas","year":"2012","unstructured":"Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mule JJ, Sarnaik AA (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35(8):615\u2013620. \n                    https:\/\/doi.org\/10.1097\/CJI.0b013e31826e8f5f","journal-title":"J Immunother"},{"issue":"17","key":"2307_CR5","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","volume":"19","author":"MJ Besser","year":"2013","unstructured":"Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19(17):4792\u20134800. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0380","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2307_CR6","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA (2016) Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol 34(20):2389\u20132397. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.66.7220","journal-title":"J Clin Oncol"},{"issue":"10","key":"2307_CR7","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346\u20132357. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.00.240","journal-title":"J Clin Oncol"},{"issue":"7","key":"2307_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907\u2013912. \n                    https:\/\/doi.org\/10.1084\/jem.20050732","journal-title":"J Exp Med"},{"issue":"2","key":"2307_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","volume":"26","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26(2):111\u2013117. \n                    https:\/\/doi.org\/10.1016\/j.it.2004.12.003","journal-title":"Trends Immunol"},{"issue":"32","key":"2307_CR10","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233\u20135239. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.5449","journal-title":"J Clin Oncol"},{"issue":"12","key":"2307_CR11","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA (2014) Il-2: the first effective immunotherapy for human cancer. J Immunol 192(12):5451\u20135458. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1490019","journal-title":"J Immunol"},{"issue":"5","key":"2307_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00262-011-1182-4","volume":"61","author":"GJ Ullenhag","year":"2012","unstructured":"Ullenhag GJ, Sadeghi AM, Carlsson B, Ahlstrom H, Mosavi F, Wagenius G, Totterman TH (2012) Adoptive T-Cell therapy for malignant melanoma patients with tils obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother 61(5):725\u2013732. \n                    https:\/\/doi.org\/10.1007\/s00262-011-1182-4","journal-title":"Cancer Immunol Immunother"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1479-5876-10-169","volume":"10","author":"E Ellebaek","year":"2012","unstructured":"Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met O, Holmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J Transl Med 10:169. \n                    https:\/\/doi.org\/10.1186\/1479-5876-10-169","journal-title":"J Transl Med"},{"issue":"15","key":"2307_CR14","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Holmich LR, Hendel HW, Met O, Andersen MH, Thor Straten P, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated Il2 regimen. Clin Cancer Res 22(15):3734\u20133745. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1879","journal-title":"Clin Cancer Res"},{"issue":"36","key":"2307_CR15","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol"},{"issue":"2","key":"2307_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1). Eur J Cancer 45(2):228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"23","key":"2307_CR17","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412\u20137420. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2307_CR18","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","volume":"21","author":"JC Yang","year":"2003","unstructured":"Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127\u20133132. \n                    https:\/\/doi.org\/10.1200\/jco.2003.02.122","journal-title":"J Clin Oncol"},{"issue":"8","key":"2307_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31(8):742\u2013751. \n                    https:\/\/doi.org\/10.1097\/CJI.0b013e31818403d5","journal-title":"J Immunother"},{"issue":"11","key":"2307_CR20","doi-asserted-by":"publisher","first-page":"e13940","DOI":"10.1371\/journal.pone.0013940","volume":"5","author":"LT Nguyen","year":"2010","unstructured":"Nguyen LT, Yen PH, Nie J, Liadis N, Ghazarian D, Al-Habeeb A, Easson A, Leong W, Lipa J, McCready D, Reedijk M, Hogg D, Joshua AM, Quirt I, Messner H, Shaw P, Crump M, Sharon E, Ohashi PS (2010) Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One 5(11):e13940. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0013940","journal-title":"PLoS One"},{"issue":"24","key":"2307_CR21","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","volume":"119","author":"X Yao","year":"2012","unstructured":"Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF (2012) Levels of peripheral CD4(+)Foxp3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24):5688\u20135696. \n                    https:\/\/doi.org\/10.1182\/blood-2011-10-386482","journal-title":"Blood"},{"issue":"4","key":"2307_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22(4):433\u2013438. \n                    https:\/\/doi.org\/10.1038\/nm.4051","journal-title":"Nat Med"},{"issue":"21","key":"2307_CR23","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122(21):3344\u20133353. \n                    https:\/\/doi.org\/10.1002\/cncr.30258","journal-title":"Cancer"},{"issue":"2","key":"2307_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35(2):226\u2013235. \n                    https:\/\/doi.org\/10.1200\/jco.2016.67.9258","journal-title":"J Clin Oncol"},{"key":"2307_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0207-6","author":"O Hamid","year":"2018","unstructured":"Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M (2018) Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of keynote-001, 002, 006. Br J Cancer. \n                    https:\/\/doi.org\/10.1038\/s41416-018-0207-6","journal-title":"Br J Cancer"},{"issue":"19","key":"2307_CR26","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.1158\/1078-0432.CCR-16-1692","volume":"23","author":"M Donia","year":"2017","unstructured":"Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, Lyngaa R, Hadrup SR, Sewell AK, Svane IM (2017) PD-1(+) polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer. Clin Cancer Res 23(19):5779\u20135788. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1692","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2307_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19(6):747\u2013752. \n                    https:\/\/doi.org\/10.1038\/nm.3161","journal-title":"Nat Med"},{"issue":"1","key":"2307_CR28","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Torngren T, Kvist A, Ringner M, Svane IM, Jonsson G (2017) Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun 8(1):1738. \n                    https:\/\/doi.org\/10.1038\/s41467-017-01460-0","journal-title":"Nat Commun"},{"issue":"23","key":"2307_CR29","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189\u20132199. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1406498","journal-title":"N Engl J Med"},{"issue":"6257","key":"2307_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Allen Van","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207\u2013211. \n                    https:\/\/doi.org\/10.1126\/science.aad0095","journal-title":"Science"},{"issue":"1","key":"2307_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (2016) Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35\u201344. \n                    https:\/\/doi.org\/10.1016\/j.cell.2016.02.065","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02307-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T19:07:00Z","timestamp":1581361620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02307-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02307-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"7 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Com pliance with ethical standards"}},{"value":"Anna Spreafico has served on Advisory Boards of: MERCK, Bristol-Myers Squibb, Novartis and Oncorus. Naoto Hirano reports receiving a research grant from and is a consultant for Takara Bio. Marcus O. Butler has served on Advisory Boards of: MERCK, Bristol-Myers Squibb, Novartis, Immunocore, Immunovaccine, EMD Serono and GlaxoSmithKline. Marcus O. Butler has received funding to support investigator initiated clinical trials from MERCK and Takara Bio. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was registered on clinicatrials.gov (NCT01883323). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution (University Health Network Research Ethics Board approved protocol UHN REB# 11\u20130683) and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent for protocol therapy, analysis of patient samples\u00a0and publication\u00a0was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}